un

UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance

A September 21, 2016 high level meeting of the United Nations General Assembly on antimicrobial resistance endorsed delinking the cost of R&D from the price and volume of sales. The documents from the meeting are available here: http://www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/. The relevant part of the political declaration was as follows: (c) Underline also that all research and Read more about UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance[…]

RTEmagicC_G77_poster_02.jpg

Group of 77 and China Back Delinkage in Context of Antimicrobials

During the UN high level meeting on Antimicrobial Resistance, the Group of 77 and and China read a statement that included an endorsement of delinkage: Statement delivered by His Excellency General Prayut Chan-o-cha (ret.) Prime Minister of the Kingdom of Thailand on behalf of the Group of 77 and China at the Plenary of the Read more about Group of 77 and China Back Delinkage in Context of Antimicrobials[…]

witty

GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”

At a March 17, 2016, Center for Strategic and International Studies (CSIS) event in Washington, D.C., on “The Bio-Pharma Industry and Society,” Sir Andrew Witty’s keynote address included a discussion of GSK’s decision to explore the delinkage of R&D costs from drug prices. Witty suggested that delinkage could initially be implemented in the context of Read more about GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”[…]

ellen-t-hoen-x600

Innovation and Access Requires “Delinkage”

By Ellen ‘t Hoen LLM. Medicines Law & Policy and Global Health Unit, University Medical Center Groningen, University of Groningen, The Netherlands. September 13, 2016 Solving the problems of access to high priced medicines is not possible without some serious new thinking about the way we finance the development of new medicines. Today’s predominant model Read more about Innovation and Access Requires “Delinkage”[…]

deanbaker

The Economics of Delinkage

By Dean Baker, Co-Director, the Center for Economic and Policy Research (CEPR) September 11, 2016 Every economist knows that trade tariffs are bad because they raise the price of the protected product above the free market price. The story is the same with patent monopolies on prescription drugs. However, there are two big differences. Tariffs Read more about The Economics of Delinkage[…]

bernie-500x

Senator Bernie Sanders Reaffirms Support for Delinkage

In a policy statement on HIV AIDS and in a series of tweets, Senator Bernie Sanders reaffirmed his support of the delinkage of R&D costs from drug prices.       This is from Senator Sander’s campaign 2016 statement on “Working to Create an AIDS and HIV-Free Generation.” THE PRIZE PLAN FOR HIV/AIDS As president, Bernie will Read more about Senator Bernie Sanders Reaffirms Support for Delinkage[…]